[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-339598-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-339598-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","the-g-protein-coupled-estrogen-receptor-selective-agonist-g-1-attenuates-cell-viability-and-migration-in-high-grade-serous-ovarian-cancer-cell-lines","The G-Protein-Coupled Estrogen Receptor Selective Agonist G-1 Attenuates Cell Viability and Migration in High-Grade Serous Ovarian Cancer Cell Lines","","The G-protein-coupled estrogen receptor (GPER; also known as GPR30) is evaluated as a promising estrogen receptor target in ovarian cancer, yet its functional role in the fallopian tube—the proposed origin of high-grade serous ovarian cancer (HGSC)—remains unclear. This in vitro study tests the selective GPER agonist G-1 using HGSC cell lines (OV90, OVCAR420) and the fallopian tube cell line (FT190) to assess effects on viability and migration. G-1 significantly attenuates proliferation and migration, highlighting a potential therapeutic strategy for ovarian cancer.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/the-g-protein-coupled-estrogen-receptor-selective-agonist-g-1-attenuates-cell-viability-and-migration-in-high-grade-serous-ovarian-cancer-cell-lines/339598/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/the-g-protein-coupled-estrogen-receptor-selective-agonist-g-1-attenuates-cell-viability-and-migration-in-high-grade-serous-ovarian-cancer-cell-lines/339598.png","ImageObject",300,407,{"name":42,"@type":43},"Aria","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What biological target and compound does the study focus on?","Question",{"text":63,"@type":64},"The study targets the G-protein-coupled estrogen receptor (GPER/GPR30) and evaluates the selective agonist G-1 for its effects on ovarian cancer cells.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which ovarian cancer models are used in the in vitro experiments?",{"text":68,"@type":64},"High-grade serous cancer cell lines OV90 and OVCAR420 are used, along with the fallopian tube cell line FT190 as a potential origin model for HGSC.",{"name":70,"@type":61,"acceptedAnswer":71},"What main effects does G-1 show on ovarian cancer cell behavior?",{"text":72,"@type":64},"In vitro results show attenuated cell proliferation and migration in the presence of G-1, supporting its relevance as a potential therapy.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},339598,1790457866,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":111,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":117,"preview_page_count":33,"preview_urls":144},2336464648322,"https://ap-avatar.wpscdn.com/avatar/2200025388227c56fec?_k=1778556882303663488","Communication  \nThe G-Protein-Coupled Estrogen Receptor Selective Agonist G-1 Attenuates Cell Viability and Migration in High-Grade Serous Ovarian Cancer Cell Lines  \nDonia Hanafi 1,2, Rob U. Onyenwoke 2,3,† and K. Sean Kimbro 1,2,4, *,†  \nCitation: Hanafi, D.; Onyenwoke, R.U.; Kimbro, K.S. The  \nG-Protein-Coupled Estrogen Receptor Selective Agonist G-1 Attenuates Cell Viability and Migration in  \nHigh-Grade Serous Ovarian Cancer Cell Lines. Int. J. Mol. Sci. 2024, 25, 6499. [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)ijms25126499  \nAcademic Editor: Dorota Latek  \nReceived: 13 May 2024  \nRevised: 7 June 2024  \nAccepted: 11 June 2024  \nPublished: 13 June 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Julius L. Chambers Biomedical/Biotechnology Research Institute, North Carolina Central University, Durham, NC 27707, USA; [dhanafi2023@gmail.com](dhanafi2023@gmail.com)  \n2 Department of Biological and Biomedical Sciences, North Carolina Central University, Durham, NC 27707, USA; [ronyenwo@nccu.edu](ronyenwo@nccu.edu)  \n3 Biomanufacturing Research Institute and Technology Enterprise (BRITE), North Carolina Central University, Durham, NC 27707, USA  \n4 Department of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine (MSM), Atlanta, GA 30310, USA  \n* Correspondence: [skimbro@msm.edu](skimbro@msm.edu)[ ](skimbro@msm.edu)† These authors contributed equally to this work.  \nAbstract: The G-protein-coupled estrogen receptor (GPER; G-protein-coupled estrogen receptor 30, also known as GPR30) is a novel estrogen receptor and has emerged as a promising target for ovarian cancer. GPER, a seven-transmembrane receptor, suppresses cellular viability and migration in studied ovarian cancer cells. However, its impact on the fallopian tube, which is the potential origin of high-grade serous (HGSC) ovarian cancer, has not been addressed. This study was conducted to evaluate the relationship of GPER, ovarian cancer subtypes, i.e., high-grade serous cell lines (OV90 and OVCAR420), as well as the cell type that is the potential origin of HGSC ovarian cancer (i.e., the fallopian tube cell line FT190) . The selective ligand assessed here is the agonist G-1, which was utilized in an in vitro study to characterize its effects on cellular viability and migration. As a result, this study has addressed the effect of a specific GPER agonist on cell viability, providing a better understanding of the effects of this compound on our diverse group of studied cell lines. Strikingly, attenuated cell proliferation and migration behaviors were observed in the presence of G-1 . Thus, our in vitro study reveals the impact of the origin of HGSC ovarian cancers and highlights the GPERagonist G-1 as a potential therapy for ovarian cancer.  \nKeywords: GPER receptor; therapeutic; fallopian tubes; ovarian cancer  \n1. Introduction  \nThe most lethal gynecologic carcinoma is ovarian cancer. This cancer has a 5-year survival rate of ~45%, making it the fourth most common cancer with regard to mortality among Western nations [1–3] . The identification of molecular targets could aid in developing pharmacologic therapies to improve the prognosis for ovarian cancer [4] . GPER expression is known to be significantly lower in ovarian cancer tissue compared to benign and low-malignant ovarian tumors, indicating its potential role as a biomarker for disease progression and a potential molecular target for ovarian cancer [5] . The novel GPER is a 7-transmembrane G-protein-coupled receptor [6] . Until the discovery of GPER agonistsand antagonists, it was challenging to determine the mechanisms through which GPER medi","cbCaipLsNbszECcE","https://ap.wps.com/l/cbCaipLsNbszECcE","pdf",1060288,"English","# Abstract\n# Keywords\n# Introduction","[{\"question\":\"What biological target and compound does the study focus on?\",\"answer\":\"The study targets the G-protein-coupled estrogen receptor (GPER/GPR30) and evaluates the selective agonist G-1 for its effects on ovarian cancer cells.\"},{\"question\":\"Which ovarian cancer models are used in the in vitro experiments?\",\"answer\":\"High-grade serous cancer cell lines OV90 and OVCAR420 are used, along with the fallopian tube cell line FT190 as a potential origin model for HGSC.\"},{\"question\":\"What main effects does G-1 show on ovarian cancer cell behavior?\",\"answer\":\"In vitro results show attenuated cell proliferation and migration in the presence of G-1, supporting its relevance as a potential therapy.\"}]","The G-Protein-Coupled Estrogen Receptor Selective Agonist G-1 Attenuates Cell Viability and Migration in High-Grade Serous Ovarian Cancer Cell Lines | PDF",1790031187,[145,149,153,157],{"page_no":22,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b631fdf58783ee4b461f1a38aea8be93.webp",983,1390,{"page_no":26,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8ae78305828f19f047d1dabb9a477f74.webp",982,1388,{"page_no":30,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b6cee03fae310b5de3d0387c880efb63.webp",981,1387,{"page_no":33,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a0e1968f7bd017e8a68694ec37fa5a02.webp",980,1385]